• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconbiogen

biogen

A young woman undergoes a brain scan.
Health
Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
By Lindsey LeakeFebruary 6, 2025
FDA
Health
First-of-its-kind drug for rare form of Lou Gehrig’s disease gets FDA approval
By Matthew Perrone and The Associated PressApril 25, 2023
FDA headquarters
Health
Alzheimer’s drug approval by FDA ‘rife with irregularities,’ Congress finds after 18-month investigation
By The Associated PressDecember 30, 2022
A pedestrian walks by Biogen's headquarters
Health
Congressional investigators say the FDA’s controversial approval of Biogen’s Alzheimer’s drug Aduhelm was ‘rife with irregularities’
By Fiona Rutherford, Celine Castronuovo and BloombergDecember 29, 2022
Breakthrough Alzheimer’s trial results show experimental drug significantly slows the disease
Health
Breakthrough Alzheimer’s trial results show experimental drug significantly slows the disease
By Michelle Fay Cortez and BloombergSeptember 28, 2022
Elderly man holding his medicine
Health
Inside the lobbying push to get Medicare to pay for a controversial Alzheimer’s drug
By Arthur Allen and Kaiser Health NewsFebruary 16, 2022
Biogen building
Health
Medicare ordered to reassess premium hike for Alzheimer’s drug
By Ricardo Alonso-Zaldivar and The Associated PressJanuary 10, 2022
Biogen headquarters
Health
Biogen slashes cost of Alzheimer’s drug by 50% six months after FDA approval
By Timothy Annett and BloombergDecember 20, 2021
The spread of the ‘Delta Plus’ subvariant is a reminder of where visions of our COVID future diverge
Newsletters
The spread of the ‘Delta Plus’ subvariant is a reminder of where visions of our COVID future diverge
By David MeyerNovember 18, 2021
Capsule-Doctors Covid Myths
Newsletters
Medical boards are still struggling to discipline doctors who spread COVID-19 myths
By Yasmin TayagNovember 11, 2021
Medicare-Prescription Pill Box
Newsletters
Medicare negotiating drug prices could be the game changer Americans need
By Yasmin TayagNovember 4, 2021
COVID vaccines could be the key to solving the global youth mental health emergency
Newsletters
COVID vaccines could be the key to solving the global youth mental health emergency
By Yasmin TayagOctober 28, 2021
Capsule-Booster Shots
Newsletters
Why the FDA’s ruling on mixing and matching vaccines will help more people get boosters
By Yasmin TayagOctober 21, 2021
The stalemate over patents is fueling vaccine inequity—and the pandemic
Newsletters
The stalemate over patents is fueling vaccine inequity—and the pandemic
By Yasmin TayagOctober 14, 2021
Merck-Antiviral Pill
Newsletters
Why Merck’s antiviral pill is not a silver bullet for COVID
By Yasmin TayagOctober 7, 2021
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Newsletters
The Supreme Court's birthright citizenship ruling hands the U.S. economy a $7.7 trillion winplaceholder alt text
By Diane BradyJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.